Chemoembolization of liver cancer with drug-loading microsphere 50-100μm

Abstract

Transcatheter arterial chemoembolization (TACE) is the mainstay of treatment for unresectable hepatocellular carcinoma (HCC). The efficacy of conventional TACE (cTACE) in liver metastases is not satisfactory, which might be due to the fact of embolic material used. Recently, as a new type of drug-loading microsphere, HepaSphere has been introduced in China. In this study, there were total 30 patients (18 males and 12 females) with liver cancer underwent embolization with Hepasphere microsphere. And a total of 44 TACE procedures were performed using 50-100μm HepaSphere. There were 16 patients diagnosed as HCC and 14 patients as liver metastases. The follow up period ranged from 3 to 15 months (median 10 months). Response rates were calculated on intention-to-treat basis. One month after TACE, total objective response was 63.3% and disease control rate was 86.7%. No severe complication (such as infection, liver abscess, abdominal bleeding, tumor rupture) was observed. In conclusion, chemoembolization with Hepasphere microsphere may be a safe and possibly effective palliative treatment for patients with liver cancer.

Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy

“…Furthermore, this demands a clear and strict separation from the observation and evaluation of primary liver cancers, such as HCC with a hypervascular architecture, and secondary liver malignancies, such as colorectal metastasis. With respect to the combined results (metastases and HCC) published by Sun et al for HepaSphere microspheres (Merit Medical Systems Inc., South Jordan, UT, USA) [ 20 ], our results showed a promising objective response rate of 44 %, and disease control rate of 70 %, which is worthy of further evaluation in randomized clinical trials. The safety and toxicity profile of Embocept DSM-TACE was very favorable in our cohort, which was composed of 179 DSM-TACE procedures in 50 patients with intermediate stage, non-resectable HCC.…”

Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients

“…For instance, there are many studies reporting the efficacy of DEB-TACE using HepaSpheres in HCC patients. A previous cohort study with 30 HCC patients treated by DEB-TACE using 50-100 lm HepaSpheres reveals that, at 1 month post treatment, the ORR is 63.3% and the DCR is 86.7% (Sun et al, 2017).…”

Pharmacokinetic herb-drug interactions between Aidi injection and Doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma

“…Despite improved diagnostic tools for HCC and much better survival rates of patients, the outcomes and prognoses of HCC patients remain poor because of poor liver function and advanced cancer stage. Transcatheter arterial chemoembolization (TACE) is the main treatment for unresectable HCC, and DOX is one of the commonly used drugs in TACE [25][26]. TACE is not, however, ideal as a long-term cure since it often reduces immunity, aggravates the impairment of liver function and reduces life quality of HCC patients [27].…”